An Intracerebral Microdialysis Study to Determine the Neuropharmacokinetics of Eribulin in Patients With Brain Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 11 Mar 2018
At a glance
- Drugs Eribulin (Primary)
- Indications Brain cancer
- Focus Pharmacokinetics
- 07 Feb 2018 Planned End Date changed from 1 May 2018 to 1 Sep 2018.
- 07 Feb 2018 Planned primary completion date changed from 1 May 2018 to 1 Sep 2018.
- 07 Aug 2017 Status changed from recruiting to active, no longer recruiting.